Durvalumab (Imfinzi) for metastatic bladder cancer
Regimen in use at
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Massard et al. 2016 (Study 1108) | Phase I/II (RT) | ORR: 31% (95% CI 18 to 47) |
Note: this regimen was intended for patients "who had progressed on, been ineligible for, or refused any number of prior therapies".
Immunotherapy
- Durvalumab (Imfinzi) 10 mg/kg IV over 60 minutes once on day 1
14-day cycle for up to 26 cycles (1 year). Patients could receive another 12 months of treatment if they experienced disease progression, had not received other anticancer treatment, and did not meet criteria for discontinuation.
References
- Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6. link to original article link to PMC article PubMed
